Maria Fala1, Vencel Somai1,2, Andreas Dannhorn3, Gregory Hamm3, Katherine Gibson3, Dominique-Laurent Couturier1, Richard Hesketh1, Alan J Wright1, Zoltan Takats4, Josephine Bunch5, Simon T Barry6, Richard J A Goodwin3,7, Kevin M Brindle1,8. 1. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. 2. Department of Radiology, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, United Kingdom. 3. Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge, United Kingdom. 4. Department of Digestion, Metabolism and Reproduction, Imperial College London, Sir Alexander Fleming Building, London, United Kingdom. 5. National Centre of Excellence in Mass Spectrometry Imaging (NiCE-MSI), National Physical Laboratory, Teddington, United Kingdom. 6. Bioscience, Discovery, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 7. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. 8. Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Abstract
PURPOSE: To compare carbon-13 (13 C) MRSI of hyperpolarized [1-13 C]pyruvate metabolism in a murine tumor model with mass spectrometric (MS) imaging of the corresponding tumor sections in order to cross validate these metabolic imaging techniques and to investigate the effects of pyruvate delivery and tumor lactate concentration on lactate labeling. METHODS: [1-13 C]lactate images were obtained from tumor-bearing mice, following injection of hyperpolarized [1-13 C]pyruvate, using a single-shot 3D 13 C spectroscopic imaging sequence in vivo and using desorption electrospray ionization MS imaging of the corresponding rapidly frozen tumor sections ex vivo. The images were coregistered, and levels of association were determined by means of Spearman rank correlation and Cohen kappa coefficients as well as linear mixed models. The correlation between [1-13 C]pyruvate and [1-13 C]lactate in the MRS images and between [12 C] and [1-13 C]lactate in the MS images were determined by means of Pearson correlation coefficients. RESULTS: [1-13 C]lactate images generated by MS imaging were significantly correlated with the corresponding MRS images. The correlation coefficient between [1-13 C]lactate and [1-13 C]pyruvate in the MRS images was higher than between [1-13 C]lactate and [12 C]lactate in the MS images. CONCLUSION: The inhomogeneous distribution of labeled lactate observed in the MRS images was confirmed by MS imaging of the corresponding tumor sections. The images acquired using both techniques show that the rate of 13 C label exchange between the injected pyruvate and endogenous tumor lactate pool is more correlated with the rate of pyruvate delivery to the tumor cells and is less affected by the endogenous lactate concentration.
PURPOSE: To compare carbon-13 (13 C) MRSI of hyperpolarized [1-13 C]pyruvate metabolism in a murinetumor model with mass spectrometric (MS) imaging of the corresponding tumor sections in order to cross validate these metabolic imaging techniques and to investigate the effects of pyruvate delivery and tumorlactate concentration on lactate labeling. METHODS: [1-13 C]lactate images were obtained from tumor-bearing mice, following injection of hyperpolarized [1-13 C]pyruvate, using a single-shot 3D 13 C spectroscopic imaging sequence in vivo and using desorption electrospray ionization MS imaging of the corresponding rapidly frozen tumor sections ex vivo. The images were coregistered, and levels of association were determined by means of Spearman rank correlation and Cohen kappa coefficients as well as linear mixed models. The correlation between [1-13 C]pyruvate and [1-13 C]lactate in the MRS images and between [12 C] and [1-13 C]lactate in the MS images were determined by means of Pearson correlation coefficients. RESULTS: [1-13 C]lactate images generated by MS imaging were significantly correlated with the corresponding MRS images. The correlation coefficient between [1-13 C]lactate and [1-13 C]pyruvate in the MRS images was higher than between [1-13 C]lactate and [12 C]lactate in the MS images. CONCLUSION: The inhomogeneous distribution of labeled lactate observed in the MRS images was confirmed by MS imaging of the corresponding tumor sections. The images acquired using both techniques show that the rate of 13 C label exchange between the injected pyruvate and endogenous tumorlactate pool is more correlated with the rate of pyruvate delivery to the tumor cells and is less affected by the endogenous lactate concentration.
Authors: Mikko I Kettunen; De-en Hu; Timothy H Witney; Rebekah McLaughlin; Ferdia A Gallagher; Sarah E Bohndiek; Sam E Day; Kevin M Brindle Journal: Magn Reson Med Date: 2010-04 Impact factor: 4.668
Authors: Zhen J Wang; Michael A Ohliger; Peder E Z Larson; Jeremy W Gordon; Robert A Bok; James Slater; Javier E Villanueva-Meyer; Christopher P Hess; John Kurhanewicz; Daniel B Vigneron Journal: Radiology Date: 2019-03-05 Impact factor: 11.105
Authors: David Calligaris; Diana Caragacianu; Xiaohui Liu; Isaiah Norton; Christopher J Thompson; Andrea L Richardson; Mehra Golshan; Michael L Easterling; Sandro Santagata; Deborah A Dillon; Ferenc A Jolesz; Nathalie Y R Agar Journal: Proc Natl Acad Sci U S A Date: 2014-09-22 Impact factor: 11.205
Authors: Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Peder E Z Larson; Andrea L Harzstark; Marcus Ferrone; Mark van Criekinge; Jose W Chang; Robert Bok; Ilwoo Park; Galen Reed; Lucas Carvajal; Eric J Small; Pamela Munster; Vivian K Weinberg; Jan Henrik Ardenkjaer-Larsen; Albert P Chen; Ralph E Hurd; Liv-Ingrid Odegardstuen; Fraser J Robb; James Tropp; Jonathan A Murray Journal: Sci Transl Med Date: 2013-08-14 Impact factor: 17.956
Authors: Maria Fala; Vencel Somai; Andreas Dannhorn; Gregory Hamm; Katherine Gibson; Dominique-Laurent Couturier; Richard Hesketh; Alan J Wright; Zoltan Takats; Josephine Bunch; Simon T Barry; Richard J A Goodwin; Kevin M Brindle Journal: Magn Reson Med Date: 2021-01-09 Impact factor: 4.668